If it turns out that these novel agents effectively suppress HIF1/2 activity in the clinic, it seems likely that tumours will develop resistance mechanisms, so it will be important to predict what these mechanisms are likely to be and how they might be overcome [10]. The gene discussed is HIF1A; the disease is neoplasm.